Edwards Lifesciences: Options Signal Caution Into Thursday's Print

Edwards Lifesciences heads into its October 23 earnings report with options traders showing the most defensive posture seen in months, even as the short-selling community sits largely on the sidelines.

The clearest signal heading into the print is in options. The put/call ratio has jumped to 1.19, nearly 3.5 standard deviations above its 20-day average of 1.04. That is a sharp departure from the flat, range-bound positioning that held through most of September and early October. The PCR had been tracking close to 1.03 for weeks before spiking over the past two sessions. Borrow conditions offer no reinforcement to the bears: short interest is only 1.6% of the free float, borrowing costs sit below 0.5% per annum, and availability is extraordinarily loose at over 8,000%, meaning the lending pool is essentially untapped. There is no meaningful squeeze dynamic in place.

The bull and bear debate for EW centres on two competing stories about the same company. Bulls point to the TMTT franchise, where sales grew 48.3% year-over-year and adoption of devices like Evoque continues to accelerate. Combined with TAVR growth of 10.6% and management's target of $6.4 billion to $6.8 billion in total revenue for fiscal 2026, the growth runway looks intact. Analyst sentiment has been largely constructive since the last report: Barclays initiated at Overweight with a $110 target earlier this month, UBS assumed coverage with a Buy at $110 in July, and JP Morgan lifted its target to $105 after the last print. The consensus target now stands at roughly $102, implying about 17% upside to the current price of $87.22. Bears, meanwhile, focus on margin execution. Adjusted operating margins came in at 23.7% against a consensus expectation of 25.9%, with elevated SG&A costs the primary culprit. Surgical Structural Heart also missed. The worry is that top-line growth is real but the cost structure is consuming too much of it, and any further margin slippage would undermine the premium valuation the stock carries, currently around 26 times earnings and 20 times EV/EBITDA.

Institutional ownership is concentrated but stable. BlackRock holds just over 10% and added roughly 6.2 million shares in the most recently reported period. JP Morgan Asset Management added 1.3 million shares. Vanguard's various vehicles collectively hold around 12%, though the 13G register shows a structural reorganisation of that stake rather than a directional reduction. No activist filer appears on the 13D register. On the insider side, the 90-day net position is a net sale of roughly $4.6 million in value, though most of the individual transactions are either tax-withholding events or planned 10b5-1 sales by divisional CVPs, not discretionary moves by the CEO or CFO. The most recent prior earnings print produced a 2% one-day decline that then recovered to a 3% gain over the following five sessions, a pattern that suggests post-print volatility tends to resolve upward when the initial reaction is negative.

Thursday's report is therefore less a test of whether EW can grow and more a test of whether the margin trajectory is turning, with the options market suggesting investors are paying for protection in case it is not.